Showing 2841-2850 of 5646 results for "".
- Millennial Demographics Drive Refractive Surgery Opportunity in UShttps://modernod.com/news/millennial-demographics-drive-refractive-surgery-opportunity-in-us/2479686/Wealth, health, and education are key factors in determining the opportunity for laser vision correction (LVC) procedures in the US, according to new Market Scope data. Refractive procedures are strongly driven by the country’s millennial population, and the high opportunity population is
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post
- Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMDhttps://modernod.com/news/oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd/2479697/Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration. Under the terms of
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Healthhttps://modernod.com/news/aao-announces-4-million-gift-to-aid-construction-of-a-public-museum-dedicated-to-vision-and-eye-health/2479720/The American Academy of Ophthalmology announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco. Prominent ophthalmologist Stanley M. Truhlsen, MD, launched the project with a $4 million donation. The annou
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out
- EyeMD EMR Healthcare Systems to Debut its EyeMD Electronic Medical Records 2.0 Releasehttps://modernod.com/news/eyemd-to-debut-its-eyemd-electronic-medical-records-2-0-release/2479739/EyeMD EMR Healthcare Systems, a provider of electronic medical records software designed specifically for ophthalmologists, announced the debut of EyeMD EMR 2.0 at the 2018 American Academy of Ophthalmology’s Annual Meeting in Chicago. “EyeMD EMR 2.0 is the result of years of research and
- LumiThera and Optos Announce Collaboration to Commercialize the Valeda Light Delivery System for Treating Dry AMD in Europehttps://modernod.com/news/lumithera-and-optos-announce-collaboration-to-commercialize-the-valeda-light-delivery-system-for-treating-dry-amd-in-europe/2479740/LumiThera announced a distribution agreement with Optos to exclusively distribute the Valeda Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. The announcement follows the recent CE Mark certification for the European Union (EU) for th
- Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy Studyhttps://modernod.com/news/eylea-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial/2479745/Regeneron Pharmaceuticals announced that the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its 1-year (52-week) primary endpoint and key secondary endpoints. On the primary end
- Foundation Fighting Blindness Launches Retinal Degeneration Fundhttps://modernod.com/news/foundation-fighting-blindness-launches-retinal-degeneration-fund/2479747/The Foundation Fighting Blindness announced the creation of the first Retinal Degeneration Fund (RD Fund), a wholly owned, 501(c)(3) not-for-profit subsidiary focused on making venture philanthropy investments to furt